FDA rejects Rexulti's approval for PTSD treatment, citing insufficient evidence of effectiveness in combination with sertraline. Otsuka and Lundbeck announced they are planning next steps.

Robert Gamble, CEO of RxBenefits, shares how Illuminate Rx does specialty, plus the areas they will continue to innovate on.

The FDA letter requested that a technical information update be included in the Chemistry Manufacturing and Controls (CMC) ...

Research shows older adults had 4.45 million skin cancer cases in 2021. Basal cell carcinoma is expected to double by 2050 worldwide.

Judi Health redefines health benefit management with a $400 million funding boost, enhancing transparency and efficiency for employers and health plans.

Investigators have identified the lowest dose of the immunosuppressive ATG needed to preserve beta cells in newly diagnosed children with Type 1 diabetes with the lowest side effects.

Yael Bensoussan, M.D., director of the University of South Florida Health Voice Center, discusses menopause-related voice ...

A groundbreaking NLP algorithm accurately identifies precancerous gastric and esophageal conditions from EHRs, enhancing early detection and personalized patient care.

Carbapenemase-producing Enterobacterales (CRE) surge in the U.S., with New Delhi metallo-β-lactamase (NDM) becoming a major public health threat.

The complete response letter was issued by the FDA during a routine inspection of a third-party fill-finish facility, not because of an issue with apitegromab.

Increasing the cholesterol-lowering protein ApoM in mice improved retinal health and may be the key to slowing age-related ...

An expert discusses how payers face multiple access challenges including high treatment costs exceeding $100,000 per patient, coverage restrictions through prior authorization and operational barriers ...